Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2025-10-31 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
关于实际控制人一致行动关系续期及间接控股股东部分上层股东表决权委托续期的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the renewal of the agreement on concerted action among the actual controllers of the company and the extension of the voting rights entrustment agreements at the level of an indirect controlling shareholder. It details the signing of supplementary agreements extending the validity of these arrangements, the shareholding structure, and the impact on control of the company. There is no financial data, no report attached or referenced as being published, and no mention of an earnings release or other financial report. The document is a regulatory announcement about control relationships and voting rights, which fits best under Regulatory Filings (RNS). The document length is under 5,000 characters and it is not a report itself but an announcement of corporate governance-related agreements and their renewal.
2025-10-31 Chinese
关于公司2025年前三季度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the company's profit distribution plan for the first three quarters of 2025. It details the proposed cash dividend per share, the total amount to be distributed, and the legal and procedural compliance of the plan. The document mentions that the plan will be submitted to the third extraordinary general meeting of shareholders for approval. The text is relatively short (1764 characters) and focuses on the profit distribution scheme rather than presenting full financial statements or comprehensive financial performance data. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple notification of dividend amount without detailed discussion. Instead, it is a formal announcement of the profit distribution plan, which aligns with the category of Notice of Dividend Amount (DIV).
2025-10-29 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2025 年第三季度报告' which translates to '2025 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and shareholder information for the third quarter of 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It also mentions that the report is unaudited. There is no indication that this is an announcement of a report or a certification document. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-29 Chinese
第四届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the fifth meeting of the fourth board of directors of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and voting results on several agenda items such as approval of the 2025 third quarter report, profit distribution plan, convening a shareholders meeting, and adoption of a market value management system. The document does not contain the full third quarter report or detailed financial statements but references where the full report and other announcements can be found. The document is primarily a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (1776 characters), and it is not a full financial report or earnings release but a meeting resolution announcement. Therefore, the correct classification is MANG with high confidence.
2025-10-29 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司首次公开发行前已发行部分股份上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsor (中信证券股份有限公司) regarding the unlocking and circulation of pre-IPO restricted shares of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It references regulatory approvals, shareholder commitments, shareholding changes, and compliance with Shenzhen Stock Exchange rules. The content focuses on the verification and approval of share circulation post-IPO, including shareholder lock-up commitments and shareholding structure changes. It is not a financial report, earnings release, or management discussion, but rather a regulatory compliance and verification document related to share circulation and lock-up release. This fits best under Regulatory Filings (RNS), as it is a regulatory compliance announcement and verification opinion that does not fit other specific categories like capital changes or director dealings.
2025-10-29 Chinese
上海泓博智源医药股份有限公司关于召开2025年第三次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2025 third extraordinary general meeting of shareholders for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), registration details, agenda items (such as the profit distribution proposal for the first three quarters of 2025), and attachments like proxy forms and registration forms. The document is not a report of financial results or management discussion, but rather a formal announcement to shareholders about the meeting and how to participate and vote. It does not contain financial statements or earnings data, nor is it a transcript or presentation. The document length is 3832 characters, which is relatively short and consistent with a meeting notice. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-10-29 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.